Urine Glucose Excretion Attenuates the Association Between Lipid Accumulation Product and Serum Uric Acid in Subjects with Prediabetes

References

• Chen J, Qiu SH, Guo HJ, Li W, Sun ZL. Increased urinary glucose excretion is associated with a reduced risk of hyperuricaemia. Diabet Med. 2019;36(7):902–907. doi:10.1111/dme.13956
   PubMedGoogle Scholar
• Neogi T, Dalbeth N. Patient education and engagement in treat-to-target gout care. Lancet. 2018;392(10156):1379–1381. doi:10.1016/S0140-6736(18)32415-2
   PubMed Web of Science ®Google Scholar
• Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000;283(18):2404–2410. doi:10.1001/jama.283.18.2404
   PubMed Web of Science ®Google Scholar
• De Pergola G, Cortese F, Termine G, et al. Uric acid, metabolic syndrome and atherosclerosis: the chicken or the egg, which comes first. Endocr Metab Immune Disord Drug Targets. 2018;18(3):251–259. doi:10.2174/1871530318666180212101548
   PubMedGoogle Scholar
• Cortese F, Giordano P, Scicchitano P, et al. Uric acid: from a biological advantage to a potential danger. A focus on cardiovascular effects. Vascul Pharmacol. 2019;120:106565. doi:10.1016/j.vph.2019.106565
   PubMed Web of Science ®Google Scholar
• Wu LM, He H, Chen G, et al. Associations between obesity and metabolic health with nonalcoholic fatty liver disease in elderly Chinese. Hepatobiliary Pancreat Dis Int. 2020;19(3):252–257. doi:10.1016/j.hbpd.2020.02.010
   PubMedGoogle Scholar
• Genoni G, Menegon V, Secco GG, et al. Insulin resistance, serum uric acid and metabolic syndrome are linked to cardiovascular dysfunction in pediatric obesity. Int J Cardiol. 2017;249:366–371. doi:10.1016/j.ijcard.2017.09.031
   PubMedGoogle Scholar
• Zupo R, Castellana F, Boninfante B, et al. Uric acid and potassium serum levels are independent predictors of blood pressure non-dipping in overweight or obese subjects. Nutrients. 2019;11(12):12. doi:10.3390/nu11122970
   Google Scholar
• Kim IY, Han KD, Kim DH, et al. Women with metabolic syndrome and general obesity are at a higher risk for significant hyperuricemia compared to men. J Clin Med. 2019;8:6.
   Google Scholar
• Maglio C, Peltonen M, Neovius M, et al. Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: a non-randomised, prospective, controlled intervention trial. Ann Rheum Dis. 2017;76(4):688–693. doi:10.1136/annrheumdis-2016-209958
   PubMed Web of Science ®Google Scholar
• Menni C, Migaud M, Kastenmüller G, et al. Metabolomic profiling of long-term weight change: role of oxidative stress and urate levels in weight gain. Obesity (Silver Spring). 2017;25(9):1618–1624. doi:10.1002/oby.21922
   PubMedGoogle Scholar
• Yeo C, Kaushal S, Lim B, et al. Impact of bariatric surgery on serum uric acid levels and the incidence of gout-a meta-analysis. Obes Rev. 2019;20(12):1759–1770. doi:10.1111/obr.12940
   PubMedGoogle Scholar
• Barberio AM, Alareeki A, Viner B, et al. Central body fatness is a stronger predictor of cancer risk than overall body size. Nat Commun. 2019;10(1):383. doi:10.1038/s41467-018-08159-w
   PubMedGoogle Scholar
• Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881–887. doi:10.1038/nature05488
   PubMed Web of Science ®Google Scholar
• Min Y, Ma X, Sankaran K, et al. Sex-specific association between gut microbiome and fat distribution. Nat Commun. 2019;10(1):2408. doi:10.1038/s41467-019-10440-5
   PubMed Web of Science ®Google Scholar
• Kwon S, Han AL. The correlation between the ratio of visceral fat area to subcutaneous fat area on computed tomography and lipid accumulation product as indexes of cardiovascular risk. J Obes Metab Syndr. 2019;28(3):186–193. doi:10.7570/jomes.2019.28.3.186
   PubMedGoogle Scholar
• Nascimento-Ferreira MV, Rendo-Urteaga T, Vilanova-Campelo RC, et al. The lipid accumulation product is a powerful tool to predict metabolic syndrome in undiagnosed Brazilian adults. Clin Nutr. 2017;36(6):1693–1700. doi:10.1016/j.clnu.2016.12.020
   PubMed Web of Science ®Google Scholar
• Tian S, Xu Y, Han F. Higher predictability of the lipid accumulation product than commonly used anthropometric parameters partly due to its definition. Clin Nutr. 2017;36(3):909. doi:10.1016/j.clnu.2017.03.001
   PubMedGoogle Scholar
• Dai H, Wang W, Chen R, Chen Z, Lu Y, Yuan H. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. Nutr Metab (Lond). 2017;14:49. doi:10.1186/s12986-017-0206-2
   PubMed Web of Science ®Google Scholar
• Du T, Yuan G, Zhou X, Sun X. Sex differences in the effect of HbA1c-defined diabetes on a wide range of cardiovascular disease risk factors. Ann Med. 2016;48(1–2):34–41. doi:10.3109/07853890.2015.1127406
   PubMed Web of Science ®Google Scholar
• Hosseinpanah F, Barzin M, Mirbolouk M, Abtahi H, Cheraghi L, Azizi F. Lipid accumulation product and incident cardiovascular events in a normal weight population: Tehran lipid and glucose study. Eur J Prev Cardiol. 2016;23(2):187–193. doi:10.1177/2047487314558771
   PubMedGoogle Scholar
• Wang H, Chen Y, Sun G, Jia P, Qian H, Sun Y. Validity of cardiometabolic index, lipid accumulation product, and body adiposity index in predicting the risk of hypertension in Chinese population. Postgrad Med. 2018;130(3):325–333. doi:10.1080/00325481.2018.1444901
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab. 2019;21(6):1291–1298. doi:10.1111/dom.13670
   PubMed Web of Science ®Google Scholar
• Lytvyn Y, Škrtić M, Yang GK, Yip PM, Perkins BA, Cherney DZ. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2015;308(2):F77–83. doi:10.1152/ajprenal.00555.2014
   PubMed Web of Science ®Google Scholar
• Bonsnes RW, Dana ES. On the increased uric acid clearance following the intravenous infusion of hypertonic glucose solutions. J Clin Invest. 1946;25(3):386–388. doi:10.1172/JCI101719
   Google Scholar
• Yamashita S, Matsuzawa Y, Tokunaga K, Fujioka S, Tarui S. Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int J Obes. 1986;10(4):255–264.
   PubMed Web of Science ®Google Scholar
• Chen J, Qiu S, Guo H, Li W, Sun Z. Increased waist-to-hip ratio is associated with decreased urine glucose excretion in adults with no history of diabetes. Endocrine. 2019;64(2):239–245. doi:10.1007/s12020-018-1802-2
   PubMedGoogle Scholar
• Huang X, Jiang X, Wang L, et al. Visceral adipose accumulation increased the risk of hyperuricemia among middle-aged and elderly adults: a population-based study. J Transl Med. 2019;17(1):341. doi:10.1186/s12967-019-2074-1
   PubMedGoogle Scholar
• Matsuura F, Yamashita S, Nakamura T, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism. 1998;47(8):929–933. doi:10.1016/S0026-0495(98)90346-8
   PubMed Web of Science ®Google Scholar
• Yamada A, Sato KK, Kinuhata S, et al. Association of visceral fat and liver fat with hyperuricemia. Arthritis Care Res (Hoboken). 2016;68(4):553–561. doi:10.1002/acr.22729
   PubMed Web of Science ®Google Scholar
• Porter SA, Massaro JM, Hoffmann U, Vasan RS, O’Donnel CJ, Fox CS. Abdominal subcutaneous adipose tissue: a protective fat depot. Diabetes Care. 2009;32(6):1068–1075. doi:10.2337/dc08-2280
   PubMedGoogle Scholar
• Knight TF, Senekjian HO, Sansom S, Weinman EJ. Effects of intraluminal D-glucose and probenecid on urate absorption in the rat proximal tubule. Am J Physiol. 1979;236(6):F526–529. doi:10.1152/ajprenal.1979.236.6.F526
   PubMedGoogle Scholar
• Brown E, Wilding J, Barber TM, Alam U, Cuthbertson DJ. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities. Obes Rev. 2019;20(6):816–828. doi:10.1111/obr.12841
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815–1823. doi:10.2337/dc13-3055
   PubMed Web of Science ®Google Scholar